E-ISSN: 1308-5263
The Assessment of the Long Term Hematologic Effects in Differentiated Thyroid Cancer Patients Treated with Radioactive Iodine [Turk J Hematol]
Turk J Hematol. Ahead of Print: TJH-39225 | DOI: 10.4274/tjh.galenos.2021.2020.0092  

The Assessment of the Long Term Hematologic Effects in Differentiated Thyroid Cancer Patients Treated with Radioactive Iodine

Bircan Sönmez1, Özlen Bektaş2, Nergiz Erkut2, Mehmet Sönmez2
1Department of Nuclear Medicine, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey
2Department of Hematology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey

Objective: Radioactive iodine (RAI) therapy may cause hematological abnormalities. The aim of the study is to evaluate long-term hematological changes in differentiated thyroid cancer (DTC) patients after RAI therapy.
Materials and Methods: One thousand three hundred eighty nine patients with DTC who were treated with RAI were retrospectively evaluated. Complete blood cell counts before the RAI therapy and last follow up and hematologic malignancy development were obtained from the electronic records.
Results and Conclusion: In the long term analysis, thrombocytopenia and lymphopenia were observed significantly over 60 years of age. We suggested that, these cytopenias should be surveyed more carefully in this group of age. Thrombocytopenia was observed more frequently in men. Leukopenia, thrombocytopenia and lymphopenia were observed significantly with >175 mCI doses. Thrombocytopenia and lymphopenia were observed significantly with multiple dose administration. The higher frequency of anemia, thrombocytopenia, leukopenia, neutropenia, and lymphopenia were found in patients with advanced stage disease. However patients with uncorrected proofadvanced stage disease had higher doses and multiple doses than patients with early stage disease. The rate of hematological malignancy was found to be higher than the general population.

Keywords: Radioactive iodine, thyroid cancer, cytopenia, hematologic malignancy, long term hematologic effects, thrombocytopenia, neutropenia




Corresponding Author: Özlen Bektaş, Türkiye


TOOLS
Uncorrected Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar


 



Impact Factor (2019) = 1.685